

CURRICULUM VITAE

Yun-Hee Kim, Ph.D.



Contact Information

Research Institute of National Cancer Center
Molecular Imaging & Therapy branch 323 Ilsan-ro, Ilsandong-gu, Goyang-si,
Gyeonggi-do 10408, Republic of Korea

Email: sensia37@ncc.re.kr, sensia37@gmail.com

Office: 82-31-920-2514 /2526 (Lab)

Cell: 82-10-3686-3193

Academic Appointment

- 2007.04 - present Chief Scientist,
Division of Convergence Technology, Research Institute of National Cancer Center
- 2012.03- present Associate Prof. Graduate School of Cancer Science and Policy,
National Cancer Center, Rep of Korea

Education/Training

Institution	Degree	Year(s)	Field
Kyunghee University, Seoul, Republic of Korea	B. S.	1989. 03 – 1994. 02	Biology
Yonsei University, Seoul, Republic of Korea (Advisor: Dr. Seung Soo Kim)	M.S.	1994. 09 – 1996. 08	Biochemistry, Cell biology
Pohang University of Science and Technology (POSTECH), Pohang, Republic of Korea (Advisor: Dr. Pann-Ghill Suh)	Ph.D.	2002. 03 – 2006. 02	Signal Transduction, Cell biology
POSTECH, Pohang, Republic of Korea	Post doctoral Fellow	2006. 03. – 2007.03	Signal Transduction, Cell biology,

Work Experiences

1996. 10. - 2000. 08 Samsung Biomedical Research Institute, Samsung Seoul Hospital,
Seoul, Republic of Korea

Research Interests

1. Cancer Therapy for Pancreatic Cancer
 - Aptamer-based targeting and Theranostics
 - Molecular Imaging-aided Cancer Gene Therapy
2. Human Patient-derived Preclinical Platform for Precision Medicine
3. Pancreatic Cancer Metastasis associated with Secreted Kinase and tumor microenvironment

Publication (recent 5 years)

Yin J, Jung JE, Choi SI, Kim SS, Oh YT, Kim TH, Choi E, Lee SJ, Kim H, Kim EO, Lee YS, Chang HJ, Park JY¹, Kim Y¹, Yun T, Heo K, Kim YJ, Kim H, **Kim YH***, Park JB*, Choi SW*. Inhibition of BMP signaling overcomes acquired resistance to cetuximab in oral squamous cell carcinomas. *Cancer Lett.* 2018;414:181-189

Kim MK, Woo SM, Park B, Yoon KA, **Kim YH**, Joo J, Lee WJ, Han SS, Park SJ, Kong SY. Prognostic Implications of Multiplex Detection of KRAS Mutations in Cell-Free DNA from Patients with Pancreatic Ductal Adenocarcinoma. *Clin Chem* 2018;64(4):726-734

Lee CW, Choi SI, Lee SJ, Oh YT, Park G, Park NY, Yoon KA, Kim S, **Kim D***, **Kim YH***, Suh JS. The effectiveness of ferritin as a contrast agent for cell tracking MRI in cancer mouse models. *Yonsei Med J* 2017; 58(1):51-58

Woo SM, Yoon KA, Hong EK, Park WS, Han SS, Park SJ, Joo J, Park EY, Lee JH, **Kim YH**, Kim TH, Lee WJ. DCK expression, a potential predictive biomarker in the adjuvant gemcitabine chemotherapy for biliary tract cancer after surgical resection: results from a phase II study. *Oncotarget* 2017; 8(46): 81394–81404

Kim H, Hong SH, Kim JY, Kim IC, Park YW, Lee SJ, Song SW, Kim JJ, Park G, Kim TM, **Kim YH**, Park JB, Chung J, Kim IH. Preclinical development of a humanized neutralizing antibody targeting HGF. *Exp Mol Med.* 2017;49(3):e309.

Shin SH, Park EJ, Min C, Choi SI, Jeon S, **Kim YH**, Kim D. Tracking Perfluorocarbon Nano-emulsion Delivery by ¹⁹F MRI for Precise High Intensity Focused Ultrasound Tumor Ablation. *Theranostics.* 2017;7(3):562-572

Kim YH⁺, Kim KT, Lee SJ, Hong SH, Moon JY, Yoon EK, Kim S, Kim EO, Kang SH, Kim SK, Choi SI, Goh SH, Kim D, Lee SW, Ju MH, Jeong JS, Kim IH. Image-aided Suicide Gene Therapy Utilizing Multifunctional hTERT-targeting Adenovirus for Clinical Translation in Hepatocellular Carcinoma. *Theranostics* 2016;6:357-368

Woo SM, Joo J, Kim SY, Park SJ, Han SS, Kim TH, Koh YH, Chung SH, **Kim YH**, Moon H, Hong EK, Lee WJ. Efficacy of pancreatic exocrine replacement therapy for patients with unresectable pancreatic cancer in a randomized trial. *Pancreatol* 2016;16:1099-1105

Heo K, Min SW, Sung HJ, Kim HG, Kim HJ, **Kim YH**, Choi BK, Han S, Chung S, Lee ES, Chung J, Kim IH. An aptamer-antibody complex (oligobody) as a novel delivery platform for targeted cancer therapies. *J Control Release* 2016;229:1-9

Jun DW, Hwang M, **Kim YH**, Kim KT, Kim S, Lee CH. DDRI-9: a novel DNA damage response inhibitor that blocks mitotic progression. *Oncotarget*. 2016;7:17699-17710

Kim YH*, Moon JY, Kim EO, Lee SJ, Kang SH, Kim SK, Heo K, Lee Y, Kim H, Kim KT, Kim D, Song MS, Lee SW, Lee Y, Koh SS, **Kim IH**. Efficient targeting and tumor retardation effect of pancreatic adenocarcinoma up-regulated factor (PAUF)-specific RNA replacement in pancreatic cancer mouse model. *Cancer Lett*. 2014;344(2):223-31

Yoon S⁺, **Kim YH**⁺, Kang SH, Kim SK, Lee HK, Kim H, Chung J, Kim IH. Bispecific Her2 × cotinine antibody in combination with cotinine-(histidine)₂-iodine for the pre-targeting of Her2-positive breast cancer xenografts. *J Cancer Res Clin Oncol*. 2014 ;140(2):227-33

Sung HJ, Choi S, Lee JW, Ok CY, Bae YS, **Kim YH**, Lee W, Heo K, Kim IH. Inhibition of human neutrophil activity by an RNA aptamer bound to interleukin-8. *Biomaterials*. 2014 ;35(1):578-89

Kim JM, Choi JS, **Kim YH**, Jin SH, Lim S, Jang HJ, Kim KT, Ryu SH, Suh PG. An activator of the cAMP/PKA/CREB pathway promotes osteogenesis from human mesenchymal stem cells. *J Cell Physiol*. 2013 ;228(3):617-26

Kim JM, Kim J, **Kim YH**, Kim KT, Ryu SH, Lee TG, Suh PG. Comparative secretome analysis of human bone marrow-derived mesenchymal stem cells during osteogenesis. *J Cell Physiol*. 2013 ;228(1):216-24

Lee SJ, Kim SJ, Seo HH, Shin SP, Kim D, Park CS, Kim KT, **Kim YH**, Jeong JS, Kim IH. Over-expression of miR-145 enhances the effectiveness of HSVtk gene therapy for malignant glioma. *Cancer Lett*. 2012 ;320(1):72-80

Kyun H*, **Kim YH***, Sung HJ, Li HY, Yoo CW, Kim JY, Park JY, Lee U, Nam BH, Kim EO, KimSY, Lee SH, Park JB, Choi SW. Hypoxia-induced up-regulation of apelin is associated with a poor prognosis in oral squamous cell carcinoma patients. *Oral Oncol*. 2012 ;48(6):500-6

Kim YH[†], Sung HJ, Kim S, Kim EO, Lee JW, Moon JY, Choi K, Jung JE, Lee Y, Koh SS, Rhee SG, Heo K, Kim IH. An RNA aptamer that specifically binds pancreatic adenocarcinoma up-regulated factor inhibits migration and growth of pancreatic cancer cells. *Cancer Letters* 2011;313:76-83

Kim H, Dae HM, Park C, Kim EO, Kim D, Kim IH, **Kim YH**^{*}, Choi Y^{*}. A highly sensitive magnetite nanoparticle as a simple and rapid stem cell labelling agent for MRI tracking. *J. Material. Chem.* 2011;21:7742-7747

Technical Transfer

- 1) Pancreatic cancer-targeting aptamer SQ7 (2018. Oct) JP BIO-A Inc.
- 2) Neutralizing antibody binding to epitope of HGF (2014. May) I-Bio Inc.
- 3) Trans-splicing ribozyme for liver cancer gene therapy (2013. Dec) Boryoung Pharma Inc.